The company said it will now investigate the formulation in a six-week hypertension study with multiple doses to explore its application to treat cardiovascular and other disease states beyond hypertension.
Lexaria shares were up 4.9% in recent trading.
Price: 1.72, Change: +0.09, Percent Change: +5.52
|Berenberg Bank Adjusts Kosmos Energy's Price Target ...|
|--RBC Capital Adjusts Sibanye Stillwater's Price Tar...|
|--RBC Lifts Vale to Sector Perform From Underperform...|
|--Nomura Cuts IQIYI's Price Target to $5.20 From $7....|
|--Nomura Adjusts Baidu's Price Target to $167 From $...|